Tranilast as an adjunctive therapy in hospitalized patients with severe COVID-19: a randomized controlled trial
Background Tranilast is a potential NLRP3 inflammasome inhibitor that may relieve
progressive inflammation due to COVID-19. Aim of the study To evaluate the therapeutic …
progressive inflammation due to COVID-19. Aim of the study To evaluate the therapeutic …
Best-practice IgM-and IgA-enriched immunoglobulin use in patients with sepsis
A Nierhaus, G Berlot, D Kindgen-Milles, E Müller… - Annals of intensive …, 2020 - Springer
Background Sepsis is a life-threatening organ dysfunction caused by a dysregulated host
response to infection. Despite treatment being in line with current guidelines, mortality …
response to infection. Despite treatment being in line with current guidelines, mortality …
Mortality in COVID-19 among women on hormone replacement therapy: a retrospective cohort study
H Dambha-Miller, W Hinton, CR Wilcox, M Joy… - Family …, 2022 - academic.oup.com
Background Limited recent observational data have suggested that there may be a
protective effect of oestrogen on the severity of COVID-19 disease. Our aim was to …
protective effect of oestrogen on the severity of COVID-19 disease. Our aim was to …
Effect of montelukast therapy on clinical course, pulmonary function, and mortality in patients with COVID‐19
The inflammatory/anti‐inflammatory balance has an important role in the clinical course of
severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2)(coronavirus disease …
severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2)(coronavirus disease …
CD38 in the age of COVID-19: a medical perspective
AL Horenstein, AC Faini… - Physiological Reviews, 2021 - journals.physiology.org
This medical review addresses the hypothesis that CD38/NADase is at the center of a
functional axis (ie, intracellular Ca2+ mobilization/IFNγ response/reactive oxygen species …
functional axis (ie, intracellular Ca2+ mobilization/IFNγ response/reactive oxygen species …
Intravenous immunoglobulin for the treatment of COVID-19: a promising tool
The current pandemic caused by the novel coronavirus, severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2), continues to relentlessly rage across the globe, representing a …
coronavirus 2 (SARS-CoV-2), continues to relentlessly rage across the globe, representing a …
Estrogen shields women from COVID-19 complications by reducing ER stress
Estrogen hormone acts as a potential key player in providing immunity against certain viral
infection. It is found to be associated in providing immunity against acute lungs inflammation …
infection. It is found to be associated in providing immunity against acute lungs inflammation …
Risk factors for adverse outcomes of COVID-19 patients: Possible basis for diverse responses to the novel coronavirus SARS-CoV-2
M Ghaebi, S Tahmasebi, M Jozghorbani, A Sadeghi… - Life sciences, 2021 - Elsevier
Abstract Severe coronavirus disease 2019 (COVID-19) caused by the Severe Acute
Respiratory Syndrome coronavirus 2 (SARS-CoV-2) is characterized by an unpredictable …
Respiratory Syndrome coronavirus 2 (SARS-CoV-2) is characterized by an unpredictable …
The role of passive immunization in the age of SARS-CoV-2: an update
JC Fischer, K Zänker, M van Griensven… - European Journal of …, 2020 - Springer
The rapid spread of the corona virus pandemic is an existential problem for many people in
numerous countries. So far, there is no effective vaccine protection or proven therapy …
numerous countries. So far, there is no effective vaccine protection or proven therapy …
[PDF][PDF] Improvement of SARS‐CoV‐2 symptoms following Guselkumab injection in a psoriatic patient
F Benhadou, V Del Marmol - Journal of the European Academy of …, 2020 - academia.edu
We read with great interest the publication of. 1 reporting the first case of SARS-CoV-2
infection in a young patient of 32-year-old suffering from psoriasis and psoriatic arthritis …
infection in a young patient of 32-year-old suffering from psoriasis and psoriatic arthritis …